Zacks Sell List Highlights: General Cable, Ternium, Acorda Therapeutics and Amsurg

 Zacks Sell List Highlights: General Cable, Ternium, Acorda Therapeutics and
                                    Amsurg

PR Newswire

CHICAGO, March 1, 2013

CHICAGO, March 1, 2013 /PRNewswire/ --Zacks.com releases details on a group
of stocks that are currently members of the exclusive Zacks Rank #5 List –
Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5
(Strong Sell): General Cable Corporation (NYSE:BGC)  and Ternium S.A.
(NYSE:TX). Further, Zacks announced #4 Rankings (Sell) on two other widely
held stocks: Acorda Therapeutics Inc (NASDAQ:ACOR) and Amsurg Corp
(NASDAQ:AMSG).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

To see the full Zacks #5 Rank List - Stocks to Sell Now visit:
http://at.zacks.com/?id=92

Since inception in 1988, the S&P 500 has outperformed the Zacks Rank #5 List
of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall
Street continued to tout stocks during the market declines of the last few
years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why BGC and TX have a Zacks Rank of 5 (Strong Sell) and
should most likely be sold or avoided for the next one to three months. Note
that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks
Rank universe:

General Cable Corporation (NYSE:BGC) announced fourth-quarter profit of 28
cents per share on February 25 which came behind the Zacks Consensus Estimate
by 1 cent. The diluted earnings per share also fell by 6.67% on a
year-over-year basis. The Zacks Consensus Estimate for the current year
slipped 20 cents per share to $2.81 in the last 30 days. Next year's estimate
also dipped 10 cents per share to $3.54 per share in that time span.

Ternium S.A. (NYSE:TX) posted a fourth -quarter loss of $1.29 per share on
February 20, which came in $1.72 cents wider than the average forecast. The
Zacks Consensus Estimate for 2013 fell to a profit of $2.68 per share from
$2.87 over the past month with 2 out of 7 covering analysts slashed forecasts.
Next year's forecasts slipped 13 cents to $2.97 per share in the same time
span.

Here is a synopsis of why ACOR and AMSG have a Zacks Rank of 4 (Sell) and
should also most likely be sold or avoided for the next one to three months.
Note that a #4 Sell rating is applied to 15% of all the stocks ranked by
Zacks;

Acorda Therapeutics Inc (NASDAQ:ACOR) fourth -quarter profit of 9 cents per
share, posted on February 14, and lagged analysts' projections by nearly
50.0%. For 2012, the Zacks Consensus Estimate moved down 3 cents to 71 cents
in the last 30 days as 3 out of the 8 covering analysts cut back on forecasts.
The forecast for next year slid 5 cents to $1.10 per share in the same time
span.

Amsurg Corp (NASDAQ:AMSG) reported a fourth-quarter profit of 49 cents per
share on February 25, that fell 3.92% short of the Zacks Consensus Estimate.
The full-year average forecast is currently pegged at $2.19 per share,
compared with the last 30 days projection of $2.24. Next year's forecast
dropped 12 cents per share in the same period.

Truly taking advantage of the Zacks Rank requires the understanding of how it
works. The free special report; "Zacks Rank Guide: Harnessing the Power of
Earnings Estimate Revisions" is available to provide this insightful
background. Download a free copy now to prosper in the years to come at
http://at.zacks.com/?id=93

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are
the most powerful force impacting stock prices." Since inception in 1988, #1
Rank Stocks have generated an average annual return of +28%. During the
2000-2002 bear market, Zacks #1 Rank stocks gained +43.8%, while the S&P 500
tumbled -37.6%. Also note that the Zacks Rank system has just as many Strong
Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since
1988, Zacks Rank #5 stocks have significantly underperformed the S&P 500 (2.8%
versus +9.7%). Thus, the Zacks Rank system allows investors to truly manage
portfolio trading effectively.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of
Zacks Rank Buy stocks and highlights those stocks poised to outperform the
market. Subscribe to this free newsletter today by visiting
http://at.zacks.com/?id=94

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Len Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=95

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.